Repligen Corporation $RGEN Shares Sold by Riverbridge Partners LLC

Riverbridge Partners LLC cut its position in Repligen Corporation (NASDAQ:RGEN) by 3.7% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 166,046 shares of the biotechnology company’s stock after selling 6,461 shares during the quarter. Riverbridge Partners LLC’s holdings in Repligen were worth $31,919,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Repligen during the 2nd quarter worth approximately $52,000. CoreCap Advisors LLC raised its position in Repligen by 1,275.0% during the third quarter. CoreCap Advisors LLC now owns 275 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 255 shares in the last quarter. Harbor Investment Advisory LLC raised its position in Repligen by 198.9% during the second quarter. Harbor Investment Advisory LLC now owns 523 shares of the biotechnology company’s stock valued at $71,000 after purchasing an additional 348 shares in the last quarter. Trust Co. of Vermont acquired a new position in Repligen during the second quarter valued at approximately $71,000. Finally, Allworth Financial LP bought a new stake in Repligen during the second quarter worth $71,000. Institutional investors own 97.64% of the company’s stock.

Repligen Price Performance

RGEN stock opened at $173.98 on Wednesday. The stock has a market cap of $11.12 billion, a price-to-earnings ratio of 87.72, a P/E/G ratio of 3.07 and a beta of 1.11. The company has a debt-to-equity ratio of 0.27, a current ratio of 9.88 and a quick ratio of 8.43. The company has a 50 day simple moving average of $177.26 and a 200 day simple moving average of $145.58. Repligen Corporation has a 1 year low of $100.99 and a 1 year high of $198.87.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, October 27th. The biotechnology company reported $0.53 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.07. The firm had revenue of $209.31 million for the quarter, compared to analyst estimates of $206.70 million. Repligen had a negative net margin of 1.47% and a positive return on equity of 5.49%. The company’s quarterly revenue was up 10.9% on a year-over-year basis. During the same quarter last year, the business posted $0.46 earnings per share. Research analysts anticipate that Repligen Corporation will post 2.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Zacks Research downgraded Repligen from a “strong-buy” rating to a “hold” rating in a report on Monday, September 28th. Canaccord Genuity Group lifted their price target on Repligen from $145.00 to $180.00 and gave the company a “hold” rating in a research note on Monday, October 19th. Weiss Ratings cut Repligen from a “hold (c)” rating to a “sell (d+)” rating in a report on Monday, November 2nd. Royal Bank Of Canada upped their price objective on Repligen from $185.00 to $200.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 28th. Finally, Barclays upped their price objective on Repligen from $175.00 to $225.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Repligen has a consensus rating of “Moderate Buy” and a consensus target price of $178.57.

Repligen Profile

Repligen is a life sciences company that develops and supplies technologies used in the manufacture of biologic medicines. Its products support biopharmaceutical companies and contract manufacturers in producing treatments such as monoclonal antibodies, vaccines and gene therapies. The company’s offerings span several stages of bioprocessing, including filtration, chromatography, fluid management and process analytics. Its products include filtration systems and single-use components, chromatography solutions and instruments that help monitor and control manufacturing processes.